Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Regenerative Medical Technology (RMTG) EBIT (2018 - 2025)

Historic EBIT for Regenerative Medical Technology (RMTG) over the last 8 years, with Q3 2025 value amounting to -$445761.0.

  • Regenerative Medical Technology's EBIT fell 236873.47% to -$445761.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$180269.0, marking a year-over-year increase of 5851.58%. This contributed to the annual value of $81181.0 for FY2024, which is 11135.04% up from last year.
  • According to the latest figures from Q3 2025, Regenerative Medical Technology's EBIT is -$445761.0, which was down 236873.47% from -$250086.0 recorded in Q2 2025.
  • Over the past 5 years, Regenerative Medical Technology's EBIT peaked at $380618.0 during Q4 2024, and registered a low of -$9.0 million during Q3 2021.
  • Its 5-year average for EBIT is -$770594.6, with a median of -$213981.0 in 2024.
  • In the last 5 years, Regenerative Medical Technology's EBIT tumbled by 1843381.16% in 2021 and then skyrocketed by 38170.76% in 2024.
  • Regenerative Medical Technology's EBIT (Quarter) stood at -$496565.0 in 2021, then crashed by 394.83% to -$2.5 million in 2022, then soared by 94.5% to -$135111.0 in 2023, then soared by 381.71% to $380618.0 in 2024, then plummeted by 217.12% to -$445761.0 in 2025.
  • Its EBIT was -$445761.0 in Q3 2025, compared to -$250086.0 in Q2 2025 and $134960.0 in Q1 2025.